The law firm of Finkelstein Thompson LLP is investigating potential
claims on behalf of shareholders of Forest Laboratories, Inc. (NYSE:
FRX) (“Forest Labs” or “the Company”), concerning the Company’s proposed
acquisition by Actavis plc. Under the terms of the proposal, Forest Labs
shareholders will receive $26.04 in cash plus 0.3306 shares of Actavis
common stock for each share of Forest Labs. Based on Actavis’ closing
price of $191.88 on Friday, February 14, 2014, this represents a total
consideration of $89.48 per Forest Labs share. At least one analyst has
set a target price of $91.00 for Forest Labs shares. The entire
transaction is valued at approximately $25 billion.
The investigation is focused on whether Forest Labs’ Board of Directors
breached its fiduciary duty in failing to maximize consideration to
shareholders, the potential unfairness of the consideration to
shareholders, the process by which the Board considered the transaction,
and potential conflicts of interest among the Company’s Board members.
If you are interested in discussing your rights as a Forest Labs
shareholder, or have information relating to this investigation, please
contact Finkelstein Thompson’s Washington, DC offices at (877) 337-1050
or (202) 337-8000, or by email at email@example.com.
Finkelstein Thompson LLP has spent over three decades delivering
outstanding representation to institutional and individual clients in
financial litigation, and has been appointed as lead or co-counsel in
dozens of shareholder class actions. Indeed, the firm has served in
leadership roles in cases that have recovered over $1 billion for
investors and consumers.
To learn more about Finkelstein Thompson LLP, please visit our website
Attorney advertising. Prior results do not guarantee similar outcomes.
Finkelstein Thompson LLP
Rosalee B. C. Thomas, 877-337-1050
Source: Finkelstein Thompson LLP